Biogen Idec Gains Phase II MS, Cancer Biologics Through PDL Deal

The agreement gives Biogen rights to Protein Design Labs' daclizumab, volociximab and fontolizumab.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet